GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Stevanato Group SPA (NYSE:STVN) » Definitions » Other Net Income (Loss)

Stevanato Group SPA (Stevanato Group SPA) Other Net Income (Loss) : $0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Stevanato Group SPA Other Net Income (Loss)?

Stevanato Group SPA's Other Net Income (Loss) for the three months ended in Mar. 2024 was $0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2024 was $0 Mil.

Stevanato Group SPA's quarterly Other Net Income (Loss) declined from Sep. 2023 ($0 Mil) to Dec. 2023 ($-0 Mil) but then increased from Dec. 2023 ($-0 Mil) to Mar. 2024 ($0 Mil).

Stevanato Group SPA's annual Other Net Income (Loss) stayed the same from Dec. 2021 ($0 Mil) to Dec. 2022 ($0 Mil) but then declined from Dec. 2022 ($0 Mil) to Dec. 2023 ($-0 Mil).


Stevanato Group SPA Other Net Income (Loss) Historical Data

The historical data trend for Stevanato Group SPA's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stevanato Group SPA Other Net Income (Loss) Chart

Stevanato Group SPA Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Net Income (Loss)
Get a 7-Day Free Trial - - - - -

Stevanato Group SPA Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Net Income (Loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Stevanato Group SPA Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Stevanato Group SPA Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Stevanato Group SPA's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.


Stevanato Group SPA (Stevanato Group SPA) Business Description

Traded in Other Exchanges
Address
Via Molinella 17, Piombino Dese, Padua, ITA, 35017
Stevanato Group SPA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. Stevanato's revenue is geographically diversified, with 60% of sales from Europe, the Middle East and Africa (EMEA), 27% in North America, 10% in Asia-Pacific (APAC), and 3% from South America. It has two segments Biopharmaceutical and Diagnostic Solutions and Engineering.